Navigation Links
Reliance Group to Develop Specialty Blood Products

New Delhi: Reliance Life Sciences, the biotechnology venture of Mukesh Ambani's Reliance Group, is developing specialty plasma proteins or blood products and building// a world class manufacturing unit to produce them.

It has been encouraged to set up a manufacturing unit due to the response to its Factor VII product, which is proving a boon for hemophiliacs who have deficiency of Factor VII in their blood that leads to serious blood clotting disorders.

"Encouraged by the market response, we are now developing specialty plasma proteins as well as building a large scale plasma protein manufacturing facility," K.V. Subramaniam, president and CEO of Reliance Life Sciences said in a statement Monday.

Plasma is the storage and transport medium of clotting factors. Its protein content is necessary to maintain the oncotic pressure of the blood, which 'holds' the serum within the vessels.

Until recently plasma proteins including Factor VII were mostly being imported.

Reliance Life Sciences is now meeting this demand through indigenous research and development.

It is manufacturing many of the plasma proteins - Albumin, Intravenous Immunoglobulin G, Factor VII, Fibrin sealant and Virus inactivated plasma - in its pilot scale facility in Mumbai.

The new facility is expected to be operational in the second half of 2007, said Subramaniam.

On Nov 29, a hemophiliac patient was able to undergo a total knee replacement at a hospital in the capital using 40,000 international units of Factor VII manufactured by Reliance Life Sciences, he said.

The availability of indigenously manufactured plasma protein, particularly Factor VII which was earlier totally imported, has helped patients due to the lower prices, and also removed uncertainty in supplies and the short expiry of imported products.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. New Infertility test to be offered by Reliance
2. Reliance Infocomm Tied With Apollo To Provide Telemedicine Services
3. Suicide risk high in 12-17 Age Group
4. Wockhardt Group Plans Hospital In Delhi By End-2007
5. Group Suicides On The Rise In Japan
6. Yogic Moments: Age Old Yoga, Benefits All Age Groups
7. Group Jogging More Beneficial To Health Than Solo Jogging
8. Plastic Surgery Is Primetime among Ethnic Groups
9. Study Finds Online Support Groups Emotionally Benefit Women Suffering From
10. Specialist Services Can Help Ethnic Groups To Tackle Alcohol Misuse
11. Distinct Support Services Needed, To Resurrect Ethnic Groups from Alcohol Abuse
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, ... University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) ... program, developed in association with efforts by the American College of Surgeons, U.S. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... laboratory instruments are critical to ensuring high-quality results and maintaining GMP and USP ... of Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... 28, 2017 , ... With less than 10,000 dermatologists in the United States ... be limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... customer online, today released its inaugural survey on the State of Acne in America. ...
(Date:3/28/2017)... ... , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in Ohio ... country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics National ... helped propel the clinic from a small start-up to number 78 in the country ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work hard to ... of business channels. , While many results are clear, much of PR is hard ... , When it comes to measurement, firms should always take an all-inclusive approach that ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 ... research with Cambridge ... Consortium   The Milner Therapeutics Institute today announces ... Elysium Health has committed significant investment for collaborative projects with ... next four years. This is the first major research investment ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
Breaking Medicine Technology: